{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:41:54Z","timestamp":1792798914146,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jtct.2026.10.019","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:07:15Z","timestamp":1792598835000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predictors and Outcomes of Immune Effector Cell Associated Neurotoxicity Syndrome in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Aggressive B-Cell Non-Hodgkin Lymphoma"],"prefix":"10.1016","author":[{"given":"Vivek G.","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4528-6367","authenticated-orcid":false,"given":"Shakthi T.","family":"Bhaskar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7302-8299","authenticated-orcid":false,"given":"Sairah","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5910-4571","authenticated-orcid":false,"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roni","family":"Shouval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0539-4796","authenticated-orcid":false,"given":"Joseph P.","family":"McGuirk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8184-7099","authenticated-orcid":false,"given":"Richard T.","family":"Maziarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smith","family":"Kungwankiattichai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9325-432X","authenticated-orcid":false,"given":"Veronika","family":"Bachanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0748-8374","authenticated-orcid":false,"given":"David L.","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2719-0580","authenticated-orcid":false,"given":"Peter A.","family":"Riedell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8525-9641","authenticated-orcid":false,"given":"Olalekan O.","family":"Oluwole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.jtct.2026.10.019_bib0001","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: Results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"10343","key":"10.1016\/j.jtct.2026.10.019_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"Kamdar","year":"2022","journal-title":"The Lancet"},{"issue":"2","key":"10.1016\/j.jtct.2026.10.019_bib0003","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jtct.2026.10.019_bib0004","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1016\/j.jtct.2026.10.019_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2022.07.011","article-title":"Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed\/Refractory Aggressive B Cell Lymphomas","volume":"28","author":"Riedell","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"12","key":"10.1016\/j.jtct.2026.10.019_bib0006","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2023020197","article-title":"Real-world experience of CAR T-cell therapy in older patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"142","author":"Chihara","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.10.019_bib0007","doi-asserted-by":"crossref","unstructured":"Gauthier J, Gazeau N, Hirayama AV., et al. Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL. Blood. Published online April 19, 2022. doi:10.1182\/BLOOD.2021014497","DOI":"10.1182\/blood.2021014497"},{"issue":"12","key":"10.1016\/j.jtct.2026.10.019_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2021.07.002","article-title":"Real-World Experience of Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed or Refractory Aggressive B-cell Lymphomas: A Single-Institution Experience","volume":"21","author":"Ghafouri","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"19","key":"10.1016\/j.jtct.2026.10.019_bib0009","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.10.019_bib0010","doi-asserted-by":"crossref","unstructured":"Maziarz RT, Bishop MR, Tam CS, et al. Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed\/Refractory Large B-Cell Lymphoma. Journal of Clinical Oncology. Published online 2025. doi:10.1200\/JCO-25-00507","DOI":"10.1200\/JCO-25-00507"},{"issue":"5","key":"10.1016\/j.jtct.2026.10.019_bib0011","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awz053","article-title":"Neurological toxicities associated with chimeric antigen receptor T-cell therapy","volume":"142","author":"Rubin","year":"2019","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.jtct.2026.10.019_bib0012","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"issue":"26","key":"10.1016\/j.jtct.2026.10.019_bib0013","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"20","key":"10.1016\/j.jtct.2026.10.019_bib0014","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-12-893396","article-title":"Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells","volume":"133","author":"Karschnia","year":"2019","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2026.10.019_bib0015","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with car t-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"issue":"21","key":"10.1016\/j.jtct.2026.10.019_bib0016","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor\u2013modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jtct.2026.10.019_bib0017","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"issue":"14","key":"10.1016\/j.jtct.2026.10.019_bib0018","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1182\/bloodadvances.2021004575","article-title":"CRP and ferritin in addition to the EASIX score predict CAR-T\u2013related toxicity","volume":"5","author":"Greenbaum","year":"2021","journal-title":"Blood Adv"},{"issue":"17","key":"10.1016\/j.jtct.2026.10.019_bib0019","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1182\/bloodadvances.2020003885","article-title":"Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells","volume":"5","author":"Pennisi","year":"2021","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.jtct.2026.10.019_bib0020","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2024015525","article-title":"CAR T-cell reality for R\/R LBCL: challenges and challengers","volume":"9","author":"Caimi","year":"2025","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.jtct.2026.10.019_bib0021","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1016\/j.jtct.2026.10.019_bib0022","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.jtct.2026.10.019_bib0023","first-page":"1","article-title":"A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma","author":"Bachy","year":"2022","journal-title":"Nature Medicine"},{"issue":"3","key":"10.1016\/j.jtct.2026.10.019_bib0024","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/bjh.18209","article-title":"A national service for delivering CD19 CAR-Tin large B-cell lymphoma \u2013 The UK real-world experience","volume":"198","author":"Kuhnl","year":"2022","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.jtct.2026.10.019_bib0025","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000487","article-title":"Endothelial and Complement Activation As Predictors of Survival in Adult Allogeneic Hematopoietic Cell Transplantation","volume":"5","author":"Gavriilaki","year":"2021","journal-title":"Hemasphere"},{"issue":"12","key":"10.1016\/j.jtct.2026.10.019_bib0026","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood\u2013brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"issue":"12","key":"10.1016\/j.jtct.2026.10.019_bib0027","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2020.2703","article-title":"Clinical Predictors of Neurotoxicity after Chimeric Antigen Receptor T-Cell Therapy","volume":"77","author":"Rubin","year":"2020","journal-title":"JAMA Neurol"},{"issue":"11","key":"10.1016\/j.jtct.2026.10.019_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2024.08.018","article-title":"Tocilizumab Prophylaxis Following Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma","volume":"30","author":"Locke","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"10.1016\/j.jtct.2026.10.019_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2023.03.019","article-title":"Impact of Preemptive Use of Tocilizumab on Chimeric Antigen Receptor T Cell Outcomes in Non-Hodgkin Lymphoma","volume":"29","author":"De Philippis","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"10.1016\/j.jtct.2026.10.019_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2025.03.011","article-title":"Cytokine Release Syndrome and Neurotoxicity Following CD19 CAR-T in B-Cell Lymphoma","volume":"31","author":"Shouval","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.jtct.2026.10.019_bib0031","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2022008525","article-title":"Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients","volume":"7","author":"Cook","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.jtct.2026.10.019_bib0032","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13045-023-01508-3","article-title":"Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study","volume":"16","author":"Epperla","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"12","key":"10.1016\/j.jtct.2026.10.019_bib0033","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noad118","article-title":"Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cells","volume":"25","author":"Karschnia","year":"2023","journal-title":"Neuro Oncol"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726008080?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726008080?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:17:23Z","timestamp":1792797443000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726008080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":33,"alternative-id":["S2666636726008080"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.10.019","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictors and Outcomes of Immune Effector Cell Associated Neurotoxicity Syndrome in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Aggressive B-Cell Non-Hodgkin Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.10.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}